Metropolis Healthcare Limited — PPTs, 08-11-2024: Investor Presentation

Metropolis Healthcare Limited's Q2FY25 Investor Presentation highlights a 13.4% year-over-year revenue increase to INR 350 Cr, with an EBITDA margin of 26.2%. The company experienced consistent growth in B2C and B2B patient volumes, and overall test volumes increased by 8%. Metropolis plans to expand its laboratory network, aiming to add 90 labs and 2,000 service centers by FY25. Their strategic focus includes enhancing digital capabilities and driving ESG initiatives to promote sustainable growth.